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The  treatment  of  patients  with  non-
Hodgkin’s lymphoma (NHL) is often the treat-
ment of elderly patients, as most patients are
older than 65 years at diagnosis. These elderly
patients  present  particular  therapeutic  chal-
lenges, because they may be more frail and at
greater risk of treatment-related toxicity, espe-
cially anthracycline-related cardiotoxicity, than
younger  patients.  The  following  two  case
studies  illustrate  the  challenges  and  thera-
peutic  decision-making  in  managing  elderly
patients with an aggressive and an indolent
form of lymphoma. 
Case 1 - Elderly woman with
existing cardiopathy 
History 
This woman was aged 79 years at presenta-
tion.  She  had  a  history  of  congestive  car-
diopathy  and  myocardial  ischemia,  and  had
undergone angioplasty 10 years earlier. Her re-
cent history included a hospital admission due
to abdominal pain. Initial patient “work-up” re-
vealed the presence of a solid hypoechogenic
abdominal mass, of around 10 cm, on abdom-
inal ultrasound. The patient was referred for
diagnostic procedures. 
Diagnosis and staging
• Clinical  examination  showed  no  systemic
signs or symptoms. 
• Laboratory investigations showed that com-
plete blood count, hemoglobin, albumin, he-
patorenal  function,  lactate  dehydrogenase
(LDH),  beta-2  microglobulin,  and  serum
electrophoresis were all within the normal
range.
• A computed tomography (CT) scan revealed
a dishomogeneous mass with rounded mar-
gins and a longest transverse diameter of 10
cm in the left flank region of the abdomen.
The mass included the superior mesenteric
artery, with no signs of compression. 
• Diagnostic laparoscopy was performed, and
a diagnosis of diffuse large B-cell lymphoma
(DLBCL: CD20+, CD10–, CD5–) was made.
The  proliferation  index,  measured  with
MIB-1 staining, was 80%.1
• Bone marrow biopsy showed no evidence of
lymphoma. 
• A  2-dimensional  echocardiogram  showed
signs of pre-existing ischemic cardiopathy
with moderate reduction of ventricular func-
tion  and  moderate  valvular  incontinence.
The left ventricular ejection fraction (LVEF)
was 35%. 
Final diagnosis 
The final diagnosis was therefore: DLBCL,
stage IA, bulky, subdiaphragmatic unresectable
disease,  with  an  International  Prognostic
Index (IPI) of 1, due to advanced age. 
Assessment for treatment 
According  to  data  from  epidemiological
studies,  the  median  age  of  patients  with
DLBCL at the time of diagnosis is around 65
years, and one fifth of them are, like the re-
ported  case,  within  the  age  range  of  75-80
years.  Older  patients  with  DLBCL  generally
show a relatively short life expectancy: overall
median survival is around 12 months (range 2-
23) and 15% die within 3 months of diagnosis.2
However,  these  poor  results  may  vary  when
analysis is limited to patients who are initially
approached with curative intent. In such cases,
median  overall  survival  increases  to  36
months, compared with 6 months for patients
in this age range who are treated with only pal-
liative intent. The main issue in elderly DLBCL
patients is then to properly decide who is suit-
able for a full course of therapy.
The rituximab, cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP)-
21 regimen appears to be a good option for eld-
erly patients with aggressive lymphoma. The
addition of rituximab to the standard CHOP
regimen has been shown to increase its effi-
cacy, in both young and elderly patients.3-6 In
addition, although CHOP-14 was shown to be
more  effective  than  CHOP-21,7,8 interim
analyses of comparisons of R-CHOP-21 and R-
CHOP-14  have  shown  no  significant  differ-
ences  in  efficacy  between  these  two  regi-
mens.9,10 As the R-CHOP-14 regimen is more
dose intense, and may therefore be associated
with more toxicities, the R-CHOP-21 regimen
may be preferable in elderly patients. 
As this patient had existing cardiopathy and
a low LVEF, she would be at increased risk of
cardiotoxicity during anthracycline treatment.
However, her disease, due to the limited stage
and  favorable  prognostic  features,  may  be
cured, with a high chance of success, if the
standard  approach  was  adopted.  She  would
therefore probably benefit from the use of a
standard regimen adapted to her concomitant
disorders.  Among  the  different  strategies
adaptable for this patient, there is the possi-
bility of reducing the drug doses, using treat-
ment regimens specifically designed for eld-
erly patients, or using different formulations
of the active drugs, allowing reduced toxicity.
For this last strategy, the availability of the
non-pegylated liposomal doxorubicin (NPLD)
formulation  makes  it  feasible  to  substitute
conventional doxorubicin in the R-CHOP reg-
imen,  defining  a  different,  potentially  more
tolerable,  therapy,  namely  the  R-COMP  reg-
imen.  A  prospective  study  in  patients  with
lymphoma who were at risk of cardiotoxicity,
and who received R-COMP therapy, showed a
promising complete response rate of 76%, and
only one patient developed an acute grade III
cardiotoxicity.11 In  addition,  a  prospective,
non-randomized study of R-COMP in elderly
patients with DLBCL showed no changes in
LVEF, and no cardiotoxic effects of this reg-
imen  during  treatment.12 This  patient  was
therefore treated with R-COMP (NPLD dose of
50 mg/m2) for four cycles, followed by involved-
field radiation therapy. She also received pro-
phylactic granulocyte colony-stimulating factor
and erythropoietin, and prednisone was low-
ered to half dose in cycles 3 and 4 in order to
reduce steroid-related toxicity. 
Treatment outcomes and follow-up 
At the end of treatment, the patient showed
no change in LVEF, which remained at 35%, and
was assessed as having an unconfirmed com-
plete response. She was diagnosed with a pul-
monary embolism at the end of chemotherapy,
which resolved during treatment with low-mo-
lecular-weight heparin. Her LVEF has since de-
teriorated to 30%. This patient remains in com-
plete remission after 7 years.
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Case 2 - Elderly man with 
a history of cardiovascular 
disease 
History 
This 77-year-old man was admitted to hos-
pital due to abdominal pain and the pres-
ence of a palpable mass. The patient had a
history of myocardial infarction 2 years be-
fore admission, which had been treated with
coronary stenting. He had persistent arterial
hypertension. 
Diagnosis and staging 
• The patient underwent laparoscopic biopsy,
and the histologic diagnosis was grade 2 fol-
licular lymphoma (FL). 
• CT  and  positron  emission  tomography
scans confirmed the presence of an abdom-
inal  mesenteric  mass  with  pathologic
adenopathies in the mediastinum and neck. 
• Laboratory tests showed normal values for
white  blood  count,  hemoglobin,  platelets,
and erythrocyte sedimentation rate, but ele-
vated LDH and beta-2 microglobulin. 
• Bone  marrow  biopsy  revealed  several
perivascular  and  paratrabecular  lymphoid
aggregates,  comprising  B-lymphocytes  ex-
pressing CD20 and CD10. 
• A  2-dimensional  echocardiogram  showed
normal  cardiac  function,  with  an  LVEF  of
65%, and the patient had a normal stress
electrocardiogram. 
Final diagnosis 
The final diagnosis was therefore: grade 2
FL,  stage  IVA.  The  patient’s  follicular  lym-
phoma  IPI  (FLIPI)  score  was  4  (due  to  ad-
vanced age, stage, elevated LDH, and number
of nodal sites).13 His FLIPI2 score was also 4
(due  to  advanced  age,  elevated  beta-2  mi-
croglobulin,  bone  marrow  involvement,  and
longest diameter of the largest involved node
>6 cm).14
Assessment for treatment 
As  this  patient  was  generally  healthy,  he
could be expected to have a life expectancy of
around  10-15  years  if  he  did  not  have  lym-
phoma.15 Older data indicate that, for such a
patient  with  a  poor  prognosis,  the  5-year
overall survival rate would only be expected to
be  around  50%.13 However,  these  data  were
produced before the availability of rituximab,
and the use of this chemotherapy combined
with  monoclonal  antibody  has  changed  out-
comes for patients with FL. A more realistic 5-
year  overall  survival  rate  with  chemo-im-
munotherapy would be 70%. However, if the
patient has an indolent lymphoma and is in his
eighth decade, he may experience a signifi-
cant reduction in life expectancy if not properly
cured of his disease.
It is not currently clear what the optimal
chemotherapy  is  for  FL.  Some  study  data
were obtained before the widespread use of
rituximab, and others before the availability
of  the  REAL  classification  of  lymphomas,16
when FL was less strictly defined and was in-
cluded  among  other  indolent  lymphomas.
Based on the most recent data, a large pro-
portion of patients are treated with R-CHOP,
although rituximab, cyclophosphamide, vin-
cristine,  and  prednisone  (R-CVP)  and  flu-
darabine-based regimens such as rituximab,
fludarabine,  and  mitoxantrone  (R-FM)  are
also used. The FOLL05 study (NCT00774826)
is currently underway to investigate the op-
timal therapy for FL, comparing R-CHOP, R-
CVP, and R-FM in patients with stage II-IV
newly diagnosed FL. This randomized study
will provide a definite answer on which ini-
tial  treatment  should  be  proposed  for  pa-
tients  with  FL,  and  whether  anthracyclines
are also needed in this lymphoma subtype;
the final results should be available by mid-
2011. In addition, bendamustine plus ritux-
imab has produced promising results in fol-
licular  lymphoma,  with  a  better  tolerability
profile compared with R-CHOP.17
Treatment outcomes and follow-up 
In this case, the patient received R-COMP
therapy, on the assumption that he was at high
risk of cardiotoxicity if conventional doxoru-
bicin were to be used. He received six cycles of
R-COMP, with 75% of the usual dose of NPLD
during cycle 1, followed by two further doses of
rituximab (similar to the regimen found to be
effective in elderly patients with NHL).5 At the
end of treatment the patient achieved a com-
plete remission, and after 30 months of follow-
up remains in complete remission with an ex-
cellent  performance  status  and  a  conserved
quality of life. 
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